Exagen
XGN
53 hedge funds and large institutions have $120M invested in Exagen in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 5 closing their positions.
3.56% more ownership
Funds ownership: 50.88% → 54.45% (+3.6%)
5% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 19
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
2% less funds holding
Funds holding: 54 → 53 (-1)
7% less capital invested
Capital invested by funds: $129M → $120M (-$9.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$8.75M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.94M |
| 3 |
SAM
Silvercrest Asset Management
New York
|
+$2.69M |
| 4 |
CPA
Cowen Prime Advisors
New York
|
+$2.43M |
| 5 |
Morgan Stanley
New York
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$7.92M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$5.33M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.55M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.08M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $11K | +$146 | +11 | +1% |
|
52
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $5K | – | – | – |
|
53
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
|
54
Nomura Holdings
Tokyo,
Japan
| – | -$5.33M | -355,000 | Closed |
|
|
55
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3.55M | -236,000 | Closed |
|
|
PVI
56
Pura Vida Investments
New York
| – | -$772K | -51,502 | Closed |
|
57
Victory Capital Management
San Antonio,
Texas
| – | -$545K | -36,345 | Closed |
|
58
Walleye Capital
New York
| – | -$186 | -12,398 | Closed |
|
XGN Hedge Fund Activity: Q3 2021 in Review
53 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q3 2021, worth a combined $120M — down 7.2% from $129M a quarter earlier.
Fund positioning in XGN was balanced in Q3 2021: 5 funds opened new positions, 5 closed out, 20 added to existing stakes and 19 trimmed.
The largest buyer was Cowen and Company, adding an estimated $8.75M. The largest seller was Wasatch Advisors, cutting an estimated $7.92M.
- 53 institutional investors held Exagen (XGN) as of Q3 2021, down from 54 in Q2 2021.
- Funds reported $120M of Exagen stock for Q3 2021, down 7.2% quarter-over-quarter.
- 5 funds opened new Exagen positions in Q3 2021 and 5 closed out, a net change of 0 holders.
- The largest Exagen buyer in Q3 2021 was Cowen and Company, an estimated $8.75M added.
- The largest Exagen seller in Q3 2021 was Wasatch Advisors, an estimated $7.92M sold.
Based on aggregated 13F filings for Q3 2021.